Key takeaways
- Mesenchymal stem cells (MSCs) are multipotent adult cells, but current thinking is that at clinical doses they act mainly by signaling and immunomodulation rather than by becoming new tissue.
- Researcher Arnold Caplan proposed renaming them "Medicinal Signaling Cells" to reflect this signaling role.
- The human evidence is mixed and still maturing: a 2024 meta-analysis of 16 randomized trials in knee osteoarthritis found little-to-no meaningful benefit for pain or function (moderate-certainty evidence).
- Large phase 3 trials are now testing specific MSC products against standard care, including the completed MILES trial (475 participants) and the ongoing AlloJoin trial (520 participants).
- Much of the strongest support remains mechanistic or preclinical, with clearer human signals in specific settings such as graft-versus-host disease and Crohn's perianal fistulas.
- Anyone considering MSC therapy should do so under qualified physician oversight, with realistic expectations grounded in the current science.
What is MSC therapy?
Mesenchymal stem cells, or MSCs, are a type of adult cell originally identified for their ability to give rise to several tissue types. A foundational 1999 study published in Science demonstrated the multilineage potential of adult human MSCs, showing they could differentiate into lineages such as bone, cartilage, and fat under the right laboratory conditions. That discovery is part of why MSCs became one of the most widely studied cell types in regenerative medicine.
MSC therapy refers broadly to approaches that use these cells to influence injury, inflammation, or tissue repair. MSCs have been studied extensively across many conditions, and how strong the evidence is depends on the condition: strongest in a few specific settings, and still emerging in others.
How MSCs are thought to work
Early excitement around MSCs assumed they would work by engrafting at a site of injury and physically rebuilding damaged tissue. The science has since shifted. An influential 2011 review in Cell Stem Cell described the MSC as an "injury drugstore," proposing that these cells act mainly by secreting bioactive, immunomodulatory factors rather than by becoming new tissue themselves.
This reframing went further in 2017, when researcher Arnold Caplan argued in Stem Cells Translational Medicine that the cells were poorly named. He proposed calling them "Medicinal Signaling Cells," reflecting the view that at clinically relevant doses they signal to surrounding cells and modulate immune activity rather than differentiating into replacement tissue. In other words, the leading mechanistic hypothesis is that MSCs may influence the local environment of an injury, not rebuild it directly.
What the trials found
The human evidence is mixed, and the strongest single finding cuts against the most common use. A 2018 review in Cell Stem Cell examined why much of the preclinical promise around MSCs has not translated into clear clinical benefit, mapping the real challenges of moving these therapies from the laboratory to reliable patient outcomes.
Knee osteoarthritis is one of the most rigorously studied applications, and the results are sobering. A 2024 systematic review and meta-analysis in Osteoarthritis and Cartilage pooled 16 randomized controlled trials covering 807 patients and found little-to-no benefit for pain or function, graded as moderate-certainty evidence. Randomized trials and meta-analyses sit near the top of the evidence hierarchy, so this finding carries real weight: it does not support strong claims of benefit for knee osteoarthritis.
The research has not stopped there. Large phase 3 trials are now testing specific MSC products head-to-head against standard care. The completed MILES trial (475 participants at four US sites) compared bone marrow, adipose, and umbilical cord MSC preparations against corticosteroid injection, and the AlloJoin trial (520 participants) is comparing an allogeneic adipose-derived product against sodium hyaluronate. These larger, product-specific trials are what will sharpen the picture.
Outside knee osteoarthritis, much of the supporting work is still mechanistic, preclinical, or drawn from smaller or earlier-stage studies. The clearer human signals show up in narrow settings, notably graft-versus-host disease and complex perianal fistulas in Crohn's disease.
Where else it is being studied
Because of their immunomodulatory and signaling properties, MSCs are being studied across a range of inflammatory and degenerative conditions. The trials cited here span knee osteoarthritis, steroid-resistant graft-versus-host disease, complex perianal fistulas in Crohn's disease, systemic lupus erythematosus, multiple sclerosis, Parkinson's disease, autism spectrum disorder, and COVID-19 acute respiratory distress syndrome. The strength of the evidence varies sharply from one use to the next, so the answer depends on the specific condition rather than on MSC therapy in general.
MSC therapy is best understood as an area of active research with results that differ by condition. Decisions belong with a qualified physician after a full assessment of where the evidence is strong and where it is still developing.
The evidence
Selected references, each verified against primary sources (PubMed and ClinicalTrials.gov). Explore the full, filterable research library on our Science page.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. MSC Therapy is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.